Research programme: neurodegenerative disorders therapeutics - Herophilus
Latest Information Update: 03 Mar 2023
At a glance
- Originator Herophilus
- Class Antidementias; Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
- Research Frontotemporal dementia; Parkinson's disease
Most Recent Events
- 01 Feb 2023 Early research in Frontotemporal dementia in USA (unspecified route) (Herophilus pipeline; February 2023)
- 01 Feb 2023 Early research in Parkinson's disease in USA (unspecified route) (Herophilus pipeline; February 2023)
- 01 Feb 2023 Preclinical trials in Alzheimer's disease in USA (unspecified route) (Herophilus pipeline; February 2023)